Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer

Patients with metastatic disease receiving aromatase inhibitor plus palbociclib and with a rising ESR1 mutation may benefit from early switch to fulvestrant plus palbociclib.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news